Skip to main content
Premium Trial:

Request an Annual Quote

James Rosa, Peter Schulz-Knappe, Rudolf Reiter, Rainer Voegeli, Hans-Dieter Zucht, Jan zur Hausen, Belinda Seto

Premium

James Rosa has become vice president, strategic development of Evergreen, Colo.-based CeMines, a privately held company that is developing molecular fingerprinting technology for cancer diagnostics and therapeutics. Rose was previously director of business development at Transat Technologies. Before that, he held a variety of positions at Intel. He has also worked at Gambro Renal Products, Presearch, Wespace, Goodyear Aerospace, and Raytheon.


Peter Schulz-Knappe has become chief scientific officer and member of the executive board of BioVision. He replaces previous CSO Rudolf Reiter. Schulz-Knappe is a co-founder of Hannover, Germany-based BioVision and was CEO until April 2003. Also, Rainer Voegeli has become chief business officer and head of business development and marketing.

Voegeli previously worked at Asta Medica and Epidauros. In addition, Hans-Dieter Zucht has become chief information officer and head of bioinformatics.

BioVision, which is privately held, conducts biomarker and lead discovery using its Peptidomics technology.


Jan zur Hausen has joined the life sciences team of Deutsche Venture Capital, a Munich-based venture capital company. Zur Hausen was previously managing director of Mulligan BioCapital in Hamburg. Before joining Mulligan in 2000, he worked at MPM Asset Management in South San Francisco, and at MPM Asset Management in Cambridge, Mass. He also held positions at Hoffman-La Roche between 1992 and 1996.


Belinda Seto has been named deputy director of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health, the NIH said last month. Seto comes to the NIBIB from a nearly one-year term as acting deputy director for extramural research at the NIH, where she advised the NIH director on extramural policy and developed policies and procedures for extramural research. Seto also previously served as deputy director of the office of extramural research and the director of the OER’s office of reports and analysis during a nine-year tenure at the OER. She has worked at the NIH since 1974, after receiving her PhD in biochemistry from Purdue University.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.